Professor Alan Burnett
- Honorary Professor (School of Cancer Sciences)
email:
Alan.Burnett@glasgow.ac.uk
The University of Glasgow uses cookies for analytics and advertising. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar helps us to understand and improve our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Alan.Burnett@glasgow.ac.uk
Othus, M. et al. (2022) Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leukemia and Lymphoma, (doi: 10.1080/10428194.2022.2131416) (PMID:36226777) (Early Online Publication)
Tazi, Y. et al. (2022) Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications, 13, 4622. (doi: 10.1038/s41467-022-32103-8) (PMID:35941135)
Russell, N. H., Hills, R. K., Kjeldsen, L., Clark, R. E., Ali, S., Cahalin, P., Thomas, I. F. and Burnett, A. K. (2022) A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: results from the UK NCRI AML17 trial. British Journal of Haematology, 198(3), pp. 528-534. (doi: 10.1111/bjh.18195) (PMID:35388465)
Russell, N., Hills, R., Kjeldsen, L., Dennis, M. and Burnett, A. (2022) Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial. British Journal of Haematology, 196(6), pp. 1344-1347. (doi: 10.1111/bjh.17974) (PMID:34904225)
Dennis, M. et al. (2021) Randomised evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances, 5(24), pp. 5621-5625. (doi: 10.1182/bloodadvances.2021005038) (PMID:34597366) (PMCID:PMC8714727)
Lin, W.-Y. et al. (2021) Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 12, 6233. (doi: 10.1038/s41467-021-26551-x) (PMID:34716350)
Othus, M. et al. (2022) Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leukemia and Lymphoma, (doi: 10.1080/10428194.2022.2131416) (PMID:36226777) (Early Online Publication)
Tazi, Y. et al. (2022) Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications, 13, 4622. (doi: 10.1038/s41467-022-32103-8) (PMID:35941135)
Russell, N. H., Hills, R. K., Kjeldsen, L., Clark, R. E., Ali, S., Cahalin, P., Thomas, I. F. and Burnett, A. K. (2022) A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: results from the UK NCRI AML17 trial. British Journal of Haematology, 198(3), pp. 528-534. (doi: 10.1111/bjh.18195) (PMID:35388465)
Russell, N., Hills, R., Kjeldsen, L., Dennis, M. and Burnett, A. (2022) Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial. British Journal of Haematology, 196(6), pp. 1344-1347. (doi: 10.1111/bjh.17974) (PMID:34904225)
Dennis, M. et al. (2021) Randomised evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances, 5(24), pp. 5621-5625. (doi: 10.1182/bloodadvances.2021005038) (PMID:34597366) (PMCID:PMC8714727)
Lin, W.-Y. et al. (2021) Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 12, 6233. (doi: 10.1038/s41467-021-26551-x) (PMID:34716350)